中邮证券：首予联邦制药(03933)“买入”评级胰岛素制剂业务表现亮眼

智通财经10-29

智通财经APP获悉，中邮证券发布研报称，联邦制药(03933)是领先的综合性制药企业之一，业务延伸至生物制药和动保领域，研发布局进入收获期。预计公司25/26/27年营收为134.2/126.5/138.4亿元，同比增长-2.5%/-5.7%/9.4%、归母净利润为23.6/20.2/24.1亿元，同比增长-11.4%/-14.2%/19.4%，对应PE(汇率按1HKD=0.92RMB)为10/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2579926665?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-29 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579926665","market":"fut","top_or_hot":-1,"title":"中邮证券：首予联邦制药(03933)“买入”评级 胰岛素制剂业务表现亮眼","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中邮证券发布研报称，联邦制药(03933)是领先的综合性制药企业之一，业务延伸至生物制药和动保领域，研发布局进入收获期。预计公司25/26/27年营收为134.2/126.5/138.4亿元，同比增长-2.5%/-5.7%/9.4%、归母净利润为23.6/20.2/24.1亿元，同比增长-11.4%/-14.2%/19.4%，对应PE(汇率按1HKD=0.92RMB)为10/...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361949.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中邮证券：首予联邦制药(03933)“买入”评级 胰岛素制剂业务表现亮眼</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中邮证券：首予联邦制药(03933)“买入”评级 胰岛素制剂业务表现亮眼\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 14:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1361949.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中邮证券发布研报称，联邦制药(03933)是领先的综合性制药企业之一，业务延伸至生物制药和动保领域，研发布局进入收获期。预计公司25/26/27年营收为134.2/126.5/138.4亿元，同比增长-2.5%/-5.7%/9.4%、归母净利润为23.6/20.2/24.1亿元，同比增长-11.4%/-14.2%/19.4%，对应PE(汇率按1HKD=0.92RMB)为10/...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361949.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1361949.html","article_id":"2579926665","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579926665","pubTimestamp":1761721109,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中邮证券发布研报称，联邦制药是领先的综合性制药企业之一，业务延伸至生物制药和动保领域，研发布局进入收获期。需求影响原料药和中间体业绩，胰岛素制剂业务表现亮眼25H1拆分来看，中间体业务对外收入10.1亿元、分部利润6.3亿元，对应利润率27.5%原料药对外收入25.3亿元、分部利润2.5亿元，对应利润率27.5%;制剂对外收入25.4亿元、分部利润1.6亿元，对应利润率6.1%;许可费收入14.3亿元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","03933":"联邦制药"},"translate_title":"China Post Securities: United Laboratories (03933) was given a \"buy\" rating for the first time, and the insulin preparation business performed well","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1.5,"03933":1.5},"content_text":"智通财经APP获悉，中邮证券发布研报称，联邦制药(03933)是领先的综合性制药企业之一，业务延伸至生物制药和动保领域，研发布局进入收获期。预计公司25/26/27年营收为134.2/126.5/138.4亿元，同比增长-2.5%/-5.7%/9.4%、归母净利润为23.6/20.2/24.1亿元，同比增长-11.4%/-14.2%/19.4%，对应PE(汇率按1HKD=0.92RMB)为10/12/10倍，首次覆盖，给予“买入”评级。中邮证券主要观点如下：事件公司公布2025年上半年业绩，25H1实现收入75.2亿元(+4.8%同比增速，下同)、EBITDA为27.5亿元(+23.3%)、归母净利润18.9亿元(+27.0%)。需求影响原料药和中间体业绩，胰岛素制剂业务表现亮眼25H1拆分来看，中间体业务对外收入10.1亿元(-23.1%)、分部利润6.3亿元(含分部间销售，下同)，对应利润率27.5%(-7.2pct)原料药对外收入25.3亿元(-27.0%)、分部利润2.5亿元，对应利润率27.5%(-4.9pct);制剂对外收入25.4亿元(+6.1%)、分部利润1.6亿元，对应利润率6.1%(-4.0pct);许可费收入14.3亿元(主要来自UBT251授权诺和诺德首付款)。制剂业务中25H1人用抗生素类制剂产品收入8.9亿元(-12.1%)预计主要受集采和需求回落影响;动保业务收入5.6亿元(-15.9%)随着新基地的建设与海外注册，未来有望恢复快速增长;胰岛素制剂收入9.6亿元(+74.5%)，其中二代胰岛素4.6亿元(+110.2%)、甘精胰岛素2.9亿元(+33.7%)、门冬胰岛素1.9亿元(+74.0%)，对应胰岛素类似物销量增长90.4%，预计主要受益于国内胰岛素集采续约公司全线产品A类中标以及巴西卫生部采购订单。研发聚焦内分泌/代谢和自免领域，26年起逐步进入收获期25H1公司研发投入5.5亿元(+14.9%)，3月利拉鲁肽国内已获批上市;GLP-1/GIP/GCG三靶新药UBT251海外权益已授权诺和诺德，目前国内减重和降糖适应症II期均已完成入组、MAFLD和CKD适应症II期也已完成首个中心的启动，此前Ib期数据显示皮下QW给药12周最高剂量组经安慰剂校正平均减重16.6%;神经肽Y2受体激动剂UBT37034于7月获得美国减重适应症临床批件，动物试验显示联用减重效果显著;小分子GLP-1药物UBT48128预计26年中中美提交IND申请，临床前数据显示减重效果优于礼来Orforglipron。公司在研管线丰富，预计26/27年均有6个新品或适应症获批上市、30年后获批产品将进一步增多。风险提示：销售情况不及预期;新药研发进度不及预期;竞争压力超预期;地缘政治风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579926665","isCrawlerRequest":true}

中邮证券：首予联邦制药(03933)“买入”评级 胰岛素制剂业务表现亮眼

精彩评论

中邮证券：首予联邦制药(03933)“买入”评级胰岛素制剂业务表现亮眼